“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:
- Fundamentals of Peptide Therapeutics
- Peptide Therapeutics by Applications & Indications
- Peptides Clinical Trials Insight by Phase, Indication & Company
- Insight on 688 Peptide Drugs in Clinical Trials
- Clinical & Patent Insight on 119 Marketed Peptides
- Future Peptide Therapeutics Market Outlook
“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market. In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.
Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing. Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities. As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.
Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors. Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.
Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property. Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.
Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market. Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.